Deutsche Bank’s Avalo Therapeutics AVTX Stock Holding History
Bought
Maintained
Sold
Other funds holding AVTX
DTC
CP
TCM
AAA
FCM
ACA
Deutsche Bank's AVTX Position: Q2 2026 in Review
Deutsche Bank reduced its Avalo Therapeutics (AVTX) stake by 73% in Q2 2026, selling an estimated $1.72M and leaving 41,166 shares worth $761K. The position accounts for ﹤0.01% of the portfolio, ranked #2532.
Deutsche Bank first reported a position in AVTX in Q3 2018 and has held it in 16 quarters since. The position peaked at $2.72M in Q4 2025. 126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.
- Deutsche Bank held 41,166 shares of Avalo Therapeutics worth $761K as of Q2 2026.
- Deutsche Bank sold 108,834 Avalo Therapeutics shares in Q2 2026, an estimated $1.72M.
- Avalo Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #2532 holding.
- Deutsche Bank first reported a position in Avalo Therapeutics in Q3 2018 and has held it in 16 quarters since.
- Deutsche Bank's Avalo Therapeutics position peaked at $2.72M in Q4 2025.
- 126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.
Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.